Table 1.
Changes in patient data during the treatment period
| Case | Dapagliflozin treatment duration | Body weight (kg) | Spot urine protein/Cr ratio | Serum Cr (mg/dL)/GFR* | Serum uric acid (mg/dL) | ||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
||||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | ||
| 1 | 4 d | 67.0 | 63.5 | No data | 2.5/25 | 1.99/35 | 8.2 | 6.6 | |
| 2 | 10 wk | 81.0 | 72.0 | 0.15 | No change | 2.3/28 | 1.88/35 | 7.2 | 6.2 |
| 3 | 2 wk | 67.4 | 62.0 | 2.92 | 2.86 | 3.3/16 | 3.0/18 | 7.8 | 5.3 |
| 4 | More than 1 yr | 82.4 | 66.4 | 2.12 | 1.27 | 3.5/18 | No change | 7.2 | 5.4 |
| 5 | 3 mo | 80.0 | 71.0 | 5.35 | 4.0 | 3.0/20 | No change | 6.1 | 5.7 |
*
Estimated GFR by CKD-EPI creatinine equation (mL/min/1.73 m2).
Cr, creatinine; GFR, glomerular filtration rate.